This website uses cookies. By continuing you are agreeing to our privacy policy.

Christoph Grundner, Ph.D.

Seattle Children's Hospital
Developing a Unique Dual-Action Compound to Treat Drug-Resistant TB
Innovation Award

Tuberculosis (TB) control is threatened by the continued emergence of drug-resistant Mycobacterium tuberculosis (Mtb) strains such as multidrug-resistant TB and extensively drug-resistant TB. There are two especially promising strategies to limit the emergence of drug resistance. One is the targeting of dormant Mtb that becomes tolerant to TB drugs, meaning they become resistant to killing. The second is host-directed therapy, which involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves. We have identified a compound that kills Mtb through both approaches. We will test the effectiveness of this dually active compound in the mouse model of tuberculosis. Our hope is that this compound will impede the emergence of drug resistance.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.


Breathe Easy

Give today and your tax-deductible gift will go TWICE as far for everyone who struggles to breathe.